The Global Implications Of Open-Source Pharmaceutical Development

The pharmaceutical industry, as currently structured, is optimized for a specific outcome: return on investment for shareholders. This is not a conspiracy. It's the explicit, legal, structural purpose of publicly traded corporations. And for many applications -- consumer electronics, entertainment, fashion -- this incentive structure works tolerably well. For medicine, it produces systematic, predictable, devastating failures.

The 10/90 Gap. In the early 2000s, the Global Forum for Health Research identified what it called the 10/90 gap: less than 10% of global health research spending addressed conditions responsible for 90% of the global disease burden. Diseases of poverty -- malaria, tuberculosis, Chagas disease, leishmaniasis, sleeping sickness -- received a fraction of the R&D investment directed at conditions prevalent in wealthy markets.

This gap persists. Of 1,556 new drugs approved between 1975 and 2004, only 21 (1.3%) were specifically developed for tropical diseases and tuberculosis, according to research published in The Lancet. The market doesn't fund what can't pay it back.

Pricing. The average cost of bringing a new drug to market is disputed -- estimates range from $1 billion (Drugs for Neglected Diseases Initiative) to $2.8 billion (Tufts Center for the Study of Drug Development). The Tufts figure is widely criticized for including opportunity cost of capital and being based on proprietary data provided by the industry itself. But even at the lower estimate, the development cost creates pressure to price drugs high enough to recoup investment, which prices out billions of people.

Evergreening. Pharmaceutical companies routinely extend patent monopolies through minor modifications -- new formulations, new delivery mechanisms, new combinations -- that add little therapeutic value but reset the patent clock. This practice, documented extensively by researchers like Tahir Amin of the Initiative for Medicines, Access and Knowledge (I-MAK), keeps generics off the market and prices elevated for years or decades beyond the original patent term.

---

Drugs for Neglected Diseases Initiative (DNDi)

Founded in 2003 by Doctors Without Borders and research institutions from Brazil, India, Kenya, Malaysia, and France, DNDi operates as a not-for-profit drug development organization.

Key achievements: - Eight new treatments delivered for neglected diseases including sleeping sickness, Chagas disease, visceral leishmaniasis, malaria, and pediatric HIV. - Total cost of developing these treatments: approximately $290 million -- less than a quarter of what a single blockbuster drug costs in the private sector. - All treatments priced at or near cost, with access provisions built into agreements from the outset. - DNDi's model separates the cost of R&D from the price of the product. Development is funded by grants, government contributions, and philanthropy. Products are priced for access, not for return.

Open Source Malaria (OSM)

Launched in 2011, OSM applies open-source software principles directly to drug discovery: - All data published in real time on an open notebook platform. - No patents. All results are public domain. - Contributions from researchers at universities and institutions in over 30 countries. - Compounds identified through the project are available for anyone to develop further.

The model demonstrates that drug discovery can proceed without proprietary lock-in. It's slower than industry-funded research in some respects (less capital) but faster in others (more eyes on the problem, no redundant effort, no secrecy-driven delays).

The Medicines Patent Pool (MPP)

Created in 2010 by UNITAID, the MPP negotiates voluntary licenses with pharmaceutical patent holders to allow generic manufacturers (primarily in India) to produce affordable versions of patented medicines.

Results: - Licenses secured for HIV, hepatitis C, and COVID-19 treatments. - Generic competition through MPP licenses has reduced prices by up to 90% in some cases. - Over 150 countries covered by MPP license agreements.

The MPP works within the existing patent system rather than replacing it. It demonstrates that access and intellectual property can coexist, even if imperfectly.

COVID-19 Technology Access Pool (C-TAP)

Launched by WHO in 2020, C-TAP invited pharmaceutical companies to share vaccine and treatment technology openly. It was largely ignored by the major companies. The failure of C-TAP is as instructive as the successes of DNDi and MPP: voluntary sharing, in the absence of structural incentives, is unreliable.

---

Based on existing precedents, a global open-source pharmaceutical system would include:

1. Public Funding of R&D

Most foundational pharmaceutical research is already publicly funded. The National Institutes of Health (NIH) spends approximately $47 billion annually on biomedical research. Similar investments are made by public institutions across Europe, Asia, and elsewhere. The innovation that the private sector monetizes is overwhelmingly built on publicly generated knowledge.

The proposal: increase public R&D funding and attach open-access conditions. Any drug developed with public funding must be available under open licenses. This doesn't prevent private companies from innovating. It prevents them from privatizing publicly funded innovations.

2. Collaborative Discovery Platforms

Expand the Open Source Malaria model to other disease areas. Build shared, global platforms where researchers contribute data, share compounds, and collaborate across institutions and borders. The infrastructure exists -- platforms like GitHub for code could be adapted for molecular data.

3. Distributed Manufacturing

Generic pharmaceutical manufacturing capacity exists in India, Bangladesh, Brazil, South Africa, and elsewhere. A global open-source system would invest in expanding and quality-certifying this capacity, creating a worldwide manufacturing network that can produce any drug in the open-source library.

4. Delinkage

The most sophisticated policy proposal is "delinkage" -- separating the cost of R&D from the price of the product. Under delinkage, governments and international institutions fund R&D through prizes, grants, and advance purchase commitments. Once a drug is developed, it enters the public domain and is manufactured competitively at near-marginal cost.

The delinkage model has been endorsed by WHO consultative committees, academic health economists, and organizations including Knowledge Ecology International and MSF.

---

The primary objection to open-source pharmaceuticals is that removing patent monopolies would destroy the incentive to innovate. This objection is serious and deserves a serious response.

First, the current system is not actually producing innovation in proportion to its costs. A significant percentage of new drug approvals are incremental modifications of existing drugs, not genuinely new therapeutic breakthroughs. The pharmaceutical industry spends more on marketing than on R&D in most years. The incentive structure produces profit, not necessarily innovation.

Second, the open-source software industry provides a direct counter-example. Linux, Apache, Firefox, Python, and thousands of other open-source projects demonstrate that people and institutions will innovate without proprietary monopolies when given the right conditions: shared infrastructure, collaborative culture, and non-monetary rewards (reputation, impact, intellectual challenge).

Third, the most important pharmaceutical innovations of the twentieth century -- penicillin, the polio vaccine, insulin (as originally developed) -- were not patented by their developers. Jonas Salk famously declined to patent the polio vaccine, asking "Could you patent the sun?" The idea that patents are necessary for pharmaceutical innovation is historically recent and empirically questionable.

---

1. Supply Chain Trace: Pick a medication you or someone you know takes regularly. Research its development history. How much public funding contributed to its discovery? Who holds the patent? What does it cost in your country versus others?

2. The Salk Test: If you developed a cure for a major disease, would you patent it? What would your decision depend on? Be honest.

3. Policy Design: Draft a one-page proposal for how your country could implement a delinkage model for one disease area (e.g., diabetes, tuberculosis, hepatitis C). What would it cost? What would it save?

4. Open-Source Contribution: Visit the Open Source Malaria project (opensourcemalaria.org) or similar open-science platforms. Even if you're not a chemist, explore how the model works. What could you contribute?

---

- DNDi. (2023). Annual Report: 20 Years of Needs-Driven Innovation. - Amin, T. & Kesselheim, A. S. (2012). "Secondary Patenting of Branded Pharmaceuticals." Journal of Law, Medicine & Ethics, 40(4), 1000-1007. - Boldrin, M. & Levine, D. K. (2008). Against Intellectual Monopoly. Cambridge University Press. - WHO Consultative Expert Working Group. (2012). Research and Development to Meet Health Needs in Developing Countries. - Stiglitz, J. E. (2006). "Scrooge and Intellectual Property Rights." BMJ, 333(7582), 1279-1280.